Literature DB >> 19320752

Israeli lay persons' views on priority-setting criteria for Alzheimer's disease.

Perla Werner1.   

Abstract

AIM: The aim of this study was to assess Israeli lay persons' preferences for setting priorities for the care of Alzheimer's disease (AD).
BACKGROUND: As the knowledge about AD accumulates, and especially as more therapeutic and non-therapeutic interventions for its early diagnosis and treatment are developed, health-care costs associated with the disease rise dramatically. Therefore, setting priorities for funding these therapies, as well as other costs associated with AD is becoming an increasingly complex need.
METHODS: A convenience sample of 624 community-dwelling men and women participated in the study (mean age = 49, range = 20-90). Participants were asked how strongly they agreed or disagreed with 18 criteria that would be used to set priorities for the allocation of resources in the area of AD.
RESULTS: High-weight criteria included being a life-threatening condition and the benefit of treatment. Average-weight criteria included the severity of the disease, treatment costs and equity of access. The age of the patient also was highly rated. All other patient-related criteria were rated as low. Value orientations and education were the main variables associated with participants' preferences.
CONCLUSIONS: The lay public seems to endorse a multi-criteria decision process for the allocation of resources in the area of AD. Similar to other diseases--disease-related criteria were highly preferred. These preferences should be compared with those of other stakeholders such as clinicians and policy makers.

Entities:  

Mesh:

Year:  2009        PMID: 19320752      PMCID: PMC5060485          DOI: 10.1111/j.1369-7625.2008.00523.x

Source DB:  PubMed          Journal:  Health Expect        ISSN: 1369-6513            Impact factor:   3.377


  36 in total

1.  Citizens and rationing: analysis of a European survey.

Authors:  E Mossialos; D King
Journal:  Health Policy       Date:  1999-10       Impact factor: 2.980

Review 2.  Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.

Authors:  John B Standridge
Journal:  Clin Ther       Date:  2004-05       Impact factor: 3.393

3.  Experts disagree over NICE's approach for assessing drugs.

Authors:  Richard Hoey
Journal:  Lancet       Date:  2007-08-25       Impact factor: 79.321

Review 4.  Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.

Authors:  Pierre N Tariot
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

5.  Preferences of the public regarding cutbacks in expenditure for patient care: are there indications of discrimination against those with mental disorders?

Authors:  Georg Schomerus; Herbert Matschinger; Matthias C Angermeyer
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-01-19       Impact factor: 4.328

6.  The public's preferences concerning the allocation of financial resources to health care: results from a representative population survey in Germany.

Authors:  Herbert Matschinger; Matthias C Angermeyer
Journal:  Eur Psychiatry       Date:  2004-12       Impact factor: 5.361

7.  Economic cost of Alzheimer disease in Israel.

Authors:  Michal Schnaider Beeri; Perla Werner; Zvi Adar; Michael Davidson; Shlomo Noy
Journal:  Alzheimer Dis Assoc Disord       Date:  2002 Apr-Jun       Impact factor: 2.703

8.  Criteria for priority-setting in health care in Uganda: exploration of stakeholders' values.

Authors:  Lydia Kapiriri; Ole Frithjof Norheim
Journal:  Bull World Health Organ       Date:  2004-04-16       Impact factor: 9.408

Review 9.  Setting priorities in global child health research investments: addressing values of stakeholders.

Authors:  Lydia Kapiriri; Mark Tomlinson; Mickey Chopra; Shams El Arifeen; Robert E Black; Igor Rudan
Journal:  Croat Med J       Date:  2007-10       Impact factor: 1.351

10.  Public involvement in the priority setting activities of a wait time management initiative: a qualitative case study.

Authors:  Rebecca A Bruni; Andreas Laupacis; Wendy Levinson; Douglas K Martin
Journal:  BMC Health Serv Res       Date:  2007-11-16       Impact factor: 2.655

View more
  7 in total

Review 1.  Societal values in the allocation of healthcare resources: is it all about the health gain?

Authors:  Tania Stafinski; Devidas Menon; Deborah Marshall; Timothy Caulfield
Journal:  Patient       Date:  2011       Impact factor: 3.883

2.  Fair reckoning: a qualitative investigation of responses to an economic health resource allocation survey.

Authors:  Mita Giacomini; Jeremiah Hurley; Deirdre DeJean
Journal:  Health Expect       Date:  2012-03-06       Impact factor: 3.377

3.  Assessing the impact of deliberative processes on the views of participants: is it 'in one ear and out the other'?

Authors:  Tania Stafinski; Devidas Menon; Yutaka Yasui
Journal:  Health Expect       Date:  2012-02-02       Impact factor: 3.377

4.  Weighting Health Outcomes by Socioeconomic Position Using Stated Preferences.

Authors:  Anita Lal; Mohammad Siahpush; Marjory Moodie; Anna Peeters; Robert Carter
Journal:  Pharmacoecon Open       Date:  2018-03

5.  Health Outcome Prioritization in Alzheimer's Disease: Understanding the Ethical Landscape.

Authors:  Alex McKeown; Andrew Turner; Zuzanna Angehrn; Dianne Gove; Amanda Ly; Clementine Nordon; Mia Nelson; Claire Tochel; Brent Mittelstadt; Alex Keenan; Michael Smith; Ilina Singh
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

6.  Laypersons' Priority-Setting Preferences for Allocating a COVID-19 Patient to a Ventilator: Does a Diagnosis of Alzheimer's Disease Matter?

Authors:  Perla Werner; Ruth Landau
Journal:  Clin Interv Aging       Date:  2020-12-23       Impact factor: 4.458

7.  Multicriteria decision analysis (MCDA) in health care: a systematic review of the main characteristics and methodological steps.

Authors:  Talita D C Frazão; Deyse G G Camilo; Eric L S Cabral; Ricardo P Souza
Journal:  BMC Med Inform Decis Mak       Date:  2018-11-01       Impact factor: 2.796

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.